Matched unrelated donor transplants have an increased risk of severe graft-versus-host disease and transplantrelated mortality (TRM). ATG has been introduced to decrease GvHD and to facilitate engraftment. We conducted a retrospective analysis of 333 patients with chronic myelogenous leukemia, who were treated with Fresenius ATG (n ¼ 145, average ¼ 90 mg/kg bw, range 40-90 mg/kg bw) or standard immunosuppression without ATG (n ¼ 188). Both groups were comparable regarding distribution of age, sex, HLA-matched vs mismatched donors. ATG Fresenius led to a faster leukocyte engraftment, decreased the incidence of acute GvHD and TRM (P ¼ 0.01 and P ¼ 0.03) and led to a significant better overall survival (70 vs 57%, P ¼ 0.03). We concluded that a prospective randomized study is needed to evaluate the definite role of ATG in hemopoietic stem cell transplantation.
donor transplantation Allogeneic stem cell transplantation from an HLA-identical sibling donor has long been established as a standard method for the treatment for hematologic malignancies and severe aplastic anemia. 1, 2 The use of matched unrelated donors for bone marrow transplantation in these diseases has resulted in lower survival rates than those expected from HLA-identical sibling bone marrow transplantation. [3] [4] [5] [6] [7] [8] [9] [10] An increased incidence of acute and chronic graft-versus-host disease (GvHD) has been the major problem with matched unrelated donor transplantation for patients with hematologic diseases, particularly those of older age. Despite promising advances in the therapy of chronic myelogenous leukemia (CML) with interferon therapy and STI 571, allogeneic hemopoietic stem cell transplantation remains so far the only curative therapy for CML. 11, 12 A large retrospective analysis of unrelated donor marrow transplantation for CML reporting on 1423 patients with CML transplanted in 85 centers showed a high incidence of graft failure (9.0%) and late graft failure (6.6%), 35% of very severe acute GvHD (III-IV) and extensive cGvHD. 13 Several strategies have been employed to decrease the incidence of very severe acute GvHD seen in unrelated stem cell transplantation. The use of T-cell-depleted marrow resulted in a lower incidence of severe GvHD but a higher rate of graft failure [14] [15] [16] antithymocyte globulin given prior to transplant has been shown to modify GvHD in recipients of marrow from unrelated donors. [17] [18] [19] Owing to of the lack of randomized prospective data we undertook a retrospective analysis of matched unrelated donor transplants of CML patients in seven German centers treated with or without ATG (Fresenius).
Materials and methods

Patients population
A total of 333 consecutively transplanted patients with CML were analyzed. Of these, 145 patients had received ATG at a dose of 40 mg/kg or higher, 188 patients received no ATG. The median age was 36 and 38 years, respectively, with a range of 6-58 years. The sex distribution did not show any significant difference. Use of cell source showed a difference between the groups: Only six patients in the ATG group and 55 patients in the control group received peripheral stem cell transplants (Po0.001). HLA mismatch was seen in 18% of the donor recipients in the ATG group and 24% in the non-ATG group. A total of 71 patients received HLA-mismatched stem cell transplants. Fifty Out of the 333 patients, 50 were in accelerated phase at the time of transplant without any difference in distribution. The conditioning with total body irradiationplus cyclophosphamide vs busulfan plus cyclophosphamide was equally distributed, and there was no difference between the groups regarding CMV positivity of donors and recipients and of median follow-up (Table 1) .
HLA-typing and donor matching
HLA-A and HLA-B-antigens were typed by serologic methods. 20 HLA-DRB1 and HLA-DQB1 alleles were typed by sequence-specific oligonucleotide probes. 21, 22 Donors were matched to recipients for the serologically defined HLA-A and HLA-B-antigens as well as HLA-DRB1 alleles and HLA-DQB1 alleles. 10, [23] [24] [25] Pretransplantation lymphocyte crossmatches with patients' sera and donor cells were performed. There was a total of 71 mismatches reported in HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1, HLA-DRB1.
Marrow and blood stem cell donors
All unrelated donors were adults. They were evaluated by medical history and a physical examination and informed about the donation procedure in detail. All donors signed written informed consent. Stem cell donors received G-CSF s.c. for 4 days once or twice daily prior to leukapheresis. The leukapheresis was carried out once or twice with the aim of obtaining a minimum of 5 Â 10 6 CD34 + cells per kg body weight of the recipient. Marrow and blood stem cell collections, respectively, were transported by courier from the collection center to the transplant site in a standardized manner. 4 
Conditioning regimens
Patients received conditioning with TBI (1200-1350 cGy, given over 3 days in six fractions), followed by cyclophosphamide (120-200 mg/kg body weight) or busulfan (14-16 mg/kg body weight p.o.) plus cyclophosphamide (120 mg/kg body weight.
5,17
GvHD prophylaxis
Donor marrow or blood stem cells were not T-cell depleted. The ATG-group included all patients receiving ATG at a dose of X40 mg/kg body weight. Most patients received 90 mg/kg body weight given over 3 days. Additional GvHD prophylaxis consisted of cyclosporin A (CpA) and methotrexate (10 mg/m 2 at days 1, 3, 6) in 120 patients and additional steroids in 25 patients. Patients who did not receive ATG were treated with CsA and methotrexate (n ¼ 137), CsA, methotrexate and steroids (n ¼ 32), or combinations (n ¼ 18) ( Table 2) .
Acute and cGvHD were diagnosed and graded according to standard criteria. 5 
Relapse
Relapse was defined as recurrence chronic myeloid leukemia or the detection of the Philadelphia chromosome on two or more occassions.
Supportive care
Patients were nursed in single rooms with hepa-filtered air. Antibiotic prophylaxis consisted of ofloxacin or ciprofloxacin, and antifungal prophylaxis of fluconazole, and -in cases of prior mycotic infections -of amphotericin. Acyclovir was given as herpes prophylaxis from day 1 until day 180. Pneumocystis carinii prophylaxis consisted of either trimethoprim/sulfamethoxazol or monthly inhalation of pentamidine. All blood products were irradiated before infusion. In some centers only blood products from CMV-negative donors were given; in other centers granulocyte filters were used. Weekly monitoring of blood and urine for CMV -antigen by PCR and short-term culture was carried out. In cases of repeated positivity antiviral therapy with gancyclovir was initiated. 17 
Statistical analysis
All data in the study were gathered retrospectively. Patient outcomes were analyzed up to the date of the last reported follow-up or to the date of death. Overall survival (OS) and event-free survival (EFS) were calculated by the KaplanMeier method. 26 
Table 1
Patients' characteristics Patients who died before day 21 without engraftment were considered as not evaluable for engraftment. Patients who died after day 28 without engraftment were considered as graft failures. Survival time of patients without events was censored at last follow-up contact. 27 A multiple regression analysis was carried out to determine the factors influencing engraftment, graft failure, acute and cGvHD, hematologic relapse, survival and EFS. 28 
Results
Engraftment and graft failure
Engraftment was defined as achievement of a leukocyte count 41/nl on three consecutive days. Engraftment was achieved in 98% of cases. The median day of leukocyte engraftment was significantly earlier in the ATG group (day 17; range 10-29) compared to the non-ATG group (day 20; range 8-38) (P ¼ 0.001). Primary graft failure was observed in one patient from the ATG group and four patients from the non-ATG group. Secondary graft failure was seen in four patients from the ATG group (Table 3) .
Acute GvHD
The cumulative incidence of acute GvHD (aGvHD) at day 100 was 65% in the ATG group and 77% in the non-ATG group (P ¼ 0.01). Acute GvHD grade III-IV occurred in 12.5% of the ATG group and 22% in the non-ATG group (P ¼ 0.03).
Chronic GvHD
Patients who survived X80 days were considered at risk for cGvHD. cGvHD was seen in 54 patients of the ATG group (44%) and in 108 patients (66%) of the non-ATG group (P ¼ 0.0002).
OS, EFS, TRM and relapse
The OS at 3 years shows a significant difference in favor of the ATG group with 70%, compared to the non-ATG group with 57% (Table 5 , Figures 1-4) . EFS of 58% and 55%, respectively, was not significant. TRM was reduced in the ATG-group with 35 cases (24%) compared to the non-ATG group with 68 cases (36%) (P ¼ 0.03). The relapse rate showed a trend for ATG with 17 relapses (12%) vs 10 relapses in the non-ATG group (5%) (P ¼ 0.09).
Univariate analysis
Univariate analyses for outcome OS, EFS and TRM are shown in Table 4 . ATG vs non-ATG has a significant effect in OS and TRM, not on EFS. Other significant values are The source of stem cells did not differ significantly. A male donor had a positive impact in all three categories. HLA match vs HLA mismatch had an impact on TRM. Conditioning TBI-Cy vs Bu-Cy did not show any difference on the univariate analysis. Highly significant was the CMV status of the recipient for OS, EFS and TRM, while neither donor CMV status nor CMV infection reactivation had a significant impact. aGvHD grade 0-I compared with grade II-IV had a positive impact on OS, EFS and TRM (Table 5) . Table 6 shows relative risks (hazard ratios) for OS, EFS and TRM and the 95% confidence intervals. The use of ATG decreased the risk of death, improved EFS and reduced TRM by 50%. aGvHD grade III-IV was a significant risk factor in all three categories. cGvHD improved EFS. Patient age was inversely correlated to OS and TRM, late engraftment correlated with OS, EFS and TRM. Chronic phase CML reduced the hazard ratio for OS, EFS and TRM. A male donor decreased TRM and improved EFS. CMV status of the patient decreased EFS. The final model for time until relapse revealed a significant risk of cGvHD for conditioning with Bu-Cy compared with TBI-Cy.
Discussion
In a retrospective analysis of 333 patients who underwent matched unrelated donor transplant, we were able to show that the use of ATG (Fresenius) in the conditioning regimen decreased the incidence of acute and cGvHD and reduced TRM from 36 to 24% allowing for a 3-year OS of 70% compared to 57%. ATG did not lead to an increased rate of graft failure. The low incidence of very severe aGvHD (grade III-IV) of 12.5% compares favorably with a control group, with the 35% observed by Hansen et al, 5 and the 33% observed by McGlave et al 7 in a retrospective analysis of 1423 patients. With the use of ATG in the conditioning group, we observed no difference in the EFS of recipients of mismatched and matched unrelated donor transplant recipients, an observation we had made in a smaller unicenter group before, whereas the recipients of matched unrelated stem cell transplants who were not treated with ATG showed a higher GvHD rate, an increase in TRM and a decrease in OS as has been shown in several prior publications. 18, 5, 7 We were concerned that the uneven distribution of PBSC transplants, amounting to 4% in the ATG group and 29% in the non-ATG group, may have influenced the incidence of acute and cGvHD.
Calculating the incidence of acute and cGvHD in patients receiving bone marrow only, we found almost identical incidences to those found in the whole group of blood and marrow receipients. 
Table 5
Cause of death Polyclonal ATG preparations were first introduced for the treatment of rejection of organ transplants and subsequently for prevention of rejection and treatment of aGvHD in bone marrow transplant recipients. The use of ATG in conjunction with cyclophosphamide for conditioning of severe aplastic anemia patients helped overcome the frequent rejection seen in heavily sensitized transfused patients. 29, 30 It was seen that with the ATG conditioning the incidence of aGvHD and cGvHD was lower than expected.
Several studies have been undertaken to monitor the kinetics of ATG in bone marrow recipients.
The immunosuppressive effect of sera from patients treated with ATG on phytohemagglutinin response of normal mononuclear cells lasted up to 4 days post transplant. 31 Rabbit ATG was detectable for a period of 3-4 weeks postadministration. A newer assay detecting rabbit antibodies on Jurkat cells, a T-cell line that had served as the immunogen for the preparation of Fresenius ATG, showed activity for up to 2-3 weeks post transplant in the recipients' sera. 32 The mechanisms through which ATG might work could be by suppression of the infused donor T-cells as well as by the modification of newly formed T-cells in the early recovery period. 33 It has been shown by several groups before that a positive CMV status of the recipient predicts for decreased EFS, whereas donor CMV status is not of significance. 33, 34 There is no significant impact of CMV infection on OS, EFS and TRM. The increased mortality seen in the group of CMV-positive recipients is caused for a variety of reasons. The mechanism for a which CMV positivity leads to an increased mortality is unknown. 34, 35 Age is still a risk factor for allogeneic transplants, specifically for matched unrelated donor transplants. Newer strategies, such as reduced conditioning intensity are being explored to improve outcome in this group.
The use of a male donor has a positive impact on TRM and EFS, as described by Gratwohl et al. 36 A positive impact of female donors on relapse rate was not seen in our patient population.
Patients with cGvHD have a 50% reduced risk of relapse. Conditioning with Bu-Cy leads to a 60% reduction in relapse rate compared with patients receiving a TBI-Cy conditioning. Patients in accelerated phase have double the risk for relapse post transplant compared with patients in chronic phase. The trend towards a higher relapse rate in the ATG group (12%) compared with the non-ATG group (5%) does not impact on OS since relapses after allogeneic donor transplantation may be successfully treated by donor lymphocyte infusions. 37, 38 Several studies are currently ongoing to decrease the widely used ATG dose of 90 mg/kg recipient body weight to 45 or 60 mg/kg. It remains to be seen whether the reduced doses are equally effective in prevention of GvHD in TRM and whether they decrease the relapse rate.
Our data on survival and EFS demonstrated that mismatched unrelated donor transplants were as successful as matched unrelated donor transplantation. 39 The use of ATG decreases TRM and aGvHD and increases OS.
Ways to optimize ATG use and comparison with other anti-T-cell preparations like Alemtuzumab and Thymoglobuline require development. 40, 41 Of particular importance appears to be the administration of ATG in mismatched unrelated donor transplantation, which decreases the risk of recipients of mismatched stem cells developing aGvHD and TRM, reducing it to the same level as recipients of fully matched stem cells grafts. 39 A prospective randomized study will be carried out to further determine the role of Fresenius ATG in unrelated donor transplant. 
